The fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by UV exposure or excessive sun burn.
Threshold Pharmaceuticals takes advantage of the differences in metabolic activity between cancerous and normal, healthy biological tissue.
Provectus Pharmaceuticals Uses Old Drug To Actualize Novel Therapeutics for Cancer and Skin Disorders
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
Bio-Path Holdings has developed a powerful drug delivery technology that utilizes cell-like drug carriers, termed liposomes, which avoid drug breakdown.
In 2010, NCI estimated that 207,090 women were diagnosed with breast cancer, while 39,840 women likely died from the disease.
ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Advanced Life Sciences (OTC BB: ADLS) took two steps this week toward advancing its lead drug candidate, Restanza.